Jupiter Neurosciences adds former White House adviser Tomas Philipson to board

Jupiter Neurosciences said July 7 it appointed health care economist Tomas J. Philipson to its board, effective June 26, adding former White House economic policy experience as the clinical-stage biotech advances its pipeline and strategy. The company said Philipson will help guide regulatory, reimbursement and growth decisions while serving on the audit and compensation committees.

Why it matters: - Jupiter Neurosciences is adding a board member with deep experience in health policy, economics and biopharma strategy at a time when the company is pushing clinical development and broader commercial planning. - The appointment gives Jupiter Neurosciences access to a former White House economic adviser with experience across government, academia and private-sector health care investing.

What happened: - Jupiter Neurosciences appointed Tomas J. Philipson, Ph.D., to its board of directors, effective June 26, 2026. - Philipson will serve on the Audit Committee and Compensation Committee. - The company announced the appointment on July 7, 2026. - Philipson is a former Acting Chairman of the White House Council of Economic Advisers.

The details: - Philipson served as Acting Chairman of the White House Council of Economic Advisers from June 2019 to June 2020. - He was a member of the Council from 2017 to 2020. - His government experience includes senior economic advisory roles to the FDA and CMS in 2003 and 2004. - He was appointed to the Key Indicator Commission of the U.S. Congress in 2012. - He served as a scientific adviser to the House of Representatives’ 21st Century Cures initiative in 2015 and the Biden Cancer Initiative in 2017. - Philipson holds the Daniel Levin Chair of Public Policy Emeritus at the University of Chicago. - His University of Chicago appointments included the Department of Economics, the Law School and the Harris School of Public Policy. - He co-founded Precision Health Economics LLC in 2007 and was managing partner until its acquisition in 2015. - Since June 2020, he has run TJP Economic Consulting Inc. - Since 2023, he has been managing partner of MEDA Ventures. - Philipson also serves on advisory boards for Diagnos Inc., GATC Health Corp., iRemedy Healthcare Companies, Epigenetix, Nested Knowledge, M2i Global and the Anthropic Economic Advisory Council. - His degrees include a B.A. in mathematics from Uppsala University, an M.A. in mathematics from Claremont Graduate University, and an M.A. and Ph.D. in economics from the Wharton School of the University of Pennsylvania. - Jupiter Neurosciences said Philipson’s board compensation includes a sign-on option to buy 90,000 shares and a performance-aligned retainer structured as an option to buy 446,428 shares in lieu of about $125,000 in cash over three years. - Both equity grants vest in equal quarterly installments over 36 months, subject to continued service. - Jupiter Neurosciences is a clinical-stage biopharmaceutical company focused on therapies for neurological and neurodegenerative disorders. - The company’s lead program is the Phase 2a RESET study in Parkinson’s disease. - Jupiter Neurosciences also highlighted its JOTROL program, its Nugevia portfolio and the anticipated acquisition of PharmAla’s ALA-002. - The company is listed on Nasdaq under the ticker JUNS. - Jupiter Neurosciences is a B2i Digital Featured Company, and its profile is available at the company profile. - The company’s website is More information.

Between the lines: - The board addition appears aimed at strengthening decision-making around FDA pathways, reimbursement and value creation, all of which matter for a clinical-stage biotech trying to convert pipeline progress into shareholder value. - Philipson’s mix of policy credentials and industry advisory roles suggests Jupiter Neurosciences is looking for a director who can bridge regulatory, academic and capital-markets perspectives.

What's next: - Philipson is expected to work with management and the board on strategic and clinical milestones during the second quarter of the year, according to the company. - Jupiter Neurosciences said the new director will help support its clinical programs and long-term strategy as it advances development and possible portfolio expansion. - The company also flagged the anticipated acquisition of PharmAla’s ALA-002 as part of its diversified corporate strategy.

The bottom line: - Jupiter Neurosciences is betting that a high-profile policy economist can help sharpen its boardroom oversight as the biotech pushes toward its next clinical and strategic catalysts.